{"title": "Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication", "doi": "10.1101/2020.02.10.936898", "citation_id": "2020.02.10.936898v1", "date": "2020-02-10", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.10.936898", "abstract": "<h3>ABSTRACT</h3>\n<p>The main protease of coronaviruses and the 3C protease of enteroviruses share a similar active-site architecture and a unique requirement for glutamine in the P1 position of the substrate. Because of their unique specificity and essential role in viral polyprotein processing, these proteases are suitable targets for the development of antiviral drugs. In order to obtain near-equipotent, broad-spectrum antivirals against alphacoronaviruses, betacoronaviruses, and enteroviruses, we pursued structure-based design of peptidomimetic \u03b1-ketoamides as inhibitors of main and 3C proteases. Six crystal structures of protease:inhibitor complexes were determined as part of this study. Compounds synthesized were tested against the recombinant proteases as well as in viral replicons and virus-infected cell cultures; most of them were not cell-toxic. Optimization of the P2 substituent of the \u03b1-ketoamides proved crucial for achieving near-equipotency against the three virus genera. The best near-equipotent inhibitors, <b>11u</b> (P2 = cyclopentylmethyl) and <b>11r</b> (P2 = cyclohexylmethyl), display low-micromolar EC<sub>50</sub> values against enteroviruses, alphacoronaviruses, and betacoronaviruses in cell cultures. In Huh7 cells, <b>11r</b> exhibits three-digit picomolar activity against Middle East Respiratory Syndrome coronavirus.</p>", "twitter_description": "The main protease of coronaviruses and the 3C protease of enteroviruses share a similar active-site architecture and a unique requirement for glutamine in the P1 position of the substrate. Because of their unique specificity and essential role in viral polyprotein processing, these proteases are suitable targets for the development of antiviral drugs. In order to obtain near-equipotent, broad-spectrum antivirals against alphacoronaviruses, betacoronaviruses, and enteroviruses, we pursued structure-based design of peptidomimetic \u03b1-ketoamides as inhibitors of main and 3C proteases. Six crystal structures of protease:inhibitor complexes were determined as part of this study. Compounds synthesized were tested against the recombinant proteases as well as in viral replicons and virus-infected cell cultures; most of them were not cell-toxic. Optimization of the P2 substituent of the \u03b1-ketoamides proved crucial for achieving near-equipotency against the three virus genera. The best near-equipotent inhibitors, 11u (P2 = cyclopentylmethyl) and 11r (P2 = cyclohexylmethyl), display low-micromolar EC50 values against enteroviruses, alphacoronaviruses, and betacoronaviruses in cell cultures. In Huh7 cells, 11r exhibits three-digit picomolar activity against Middle East Respiratory Syndrome coronavirus.\n\n*   3CLpro\n    :   3C-like protease;\n    3Cpro\n    :   3C protease;\n    A490\n    :   absorbance at 490 nm;\n    ap \n    :   antiperiplanar;\n    BAC\n    :   bacterial artificial chromosome;\n    CPE\n    :   cytopathic effect;\n    CVA16\n    :   Coxsackievirus A16;\n    CVB3\n    :   Coxsackievirus B3;\n    DMEM\n    :   Dulbecco\u2019s modified minimal essential medium;\n    EMEM\n    :   Eagle\u2019s minimal essential medium;\n    EV\n    :   enterovirus;\n    FIPV\n    :   Feline Infectious Peritonitis Virus;\n    FRET\n    :   fluorescence resonance energy transfer;\n    GlnLactam\n    :   glutamine lactam;\n    HCoV\n    :   human coronavirus;\n    HFMD\n    :   Hand, Foot, and Mouth Disease;\n    HRV\n    :   human rhinovirus;\n    MERS-CoV\n    :   Middle-East respiratory syndrome coronavirus;\n    Mpro\n    :   main protease;\n    Nsp5\n    :   non-structural protein 5;\n    NTR\n    :   non-translated region;\n    OD498\n    :   optical density at 498 nm;\n    PEG\n    :   polyethylene glycol;\n    RFU\n    :   relative fluorescence units;\n    Rz\n    :   ribozyme;\n    SARS\n    :   severe acute respiratory syndrome;\n    SARS-CoV\n    :   SARS coronavirus;\n    - sc \n    :   (-)-synclinal;\n    SD\n    :   standard deviation;\n    TLC\n    :   thin-layer chromatography", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.10.936898v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.10.936898v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.10.936898v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/02/10/2020.02.10.936898.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.10.936898v1", "access_rights": "restricted", "authors": ["Linlin Zhang", "Daizong Lin", "Yuri Kusov", "Yong Nian", "Qingjun Ma", "Jiang Wang", "Albrecht von Brunn", "Pieter Leyssen", "Kristina Lanko", "Johan Neyts", "Adriaan de Wilde", "Eric J. Snijder", "Hong Liu", "Rolf Hilgenfeld"]}